BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy

Published 14/07/2025, 14:20
© Reuters.

Investing.com -- BiomX (NYSE:PHGE) Inc. (NYSE American:PHGE) stock surged 60% after the clinical-stage company announced it has successfully initiated patient dosing in its Phase 2b trial evaluating BX004 for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.

The randomized, double-blind, placebo-controlled study will evaluate approximately 60 cystic fibrosis patients, with participants receiving either BX004 or placebo via inhalation twice daily for 8 weeks. The company expects topline results in the first quarter of 2026.

"This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P. aeruginosa infections who desperately need new options," said Jonathan Solomon, Chief Executive Officer of BiomX.

The trial follows encouraging Phase 1b/2a results where 14.3% of patients completely cleared infections after 10 days of treatment, including individuals who had been living with chronic infections for over a decade.

BiomX’s phage therapy targets specific pathogenic bacteria that remain a leading cause of death in cystic fibrosis patients despite modern treatments. The company has already secured Fast Track and Orphan Drug designations from the FDA for BX004.

The Phase 2b trial will measure multiple efficacy endpoints, including reduction in bacterial burden, improvements in lung function, and enhanced quality of life. BiomX anticipates feedback from the FDA in the second half of 2025 regarding plans to link bacterial reduction to clinical outcomes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.